Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B2UZ
|
||||
| Former ID |
DAP000373
|
||||
| Drug Name |
Prochlorperazine
|
||||
| Synonyms |
CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Nausea; Vomiting [ICD9: 787, 787.0; ICD10:R11] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H24ClN3S
|
||||
| InChI |
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
|
||||
| InChIKey |
WIKYUJGCLQQFNW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 58-38-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9607, 597374, 855827, 5236619, 7847559, 7980391, 8153028, 10528269, 11111685, 11111686, 11335588, 11360827, 11363734, 11364717, 11366296, 11367279, 11368858, 11369841, 11371862, 11372882, 11374482, 11375441, 11377020, 11378005, 11427138, 11461799, 11466427, 11467547, 11485069, 11486274, 11489113, 11490697, 11492787, 11494654, 14828997, 24263035, 29223995, 46509018, 47216713, 47216714, 47291072, 47291073, 47662213, 47662214, 47736410, 47810684, 47885344, 47885345, 48035042, 48416473
|
||||
| ChEBI ID |
ChEBI:8435
|
||||
| SuperDrug ATC ID |
N05AB04
|
||||
| SuperDrug CAS ID |
cas=000058388
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [3], [4] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040058. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7279). | ||||
| REF 3 | In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102. Epub 2008 Oct 15. | ||||
| REF 4 | Tardive dyskinesia as a result of long-term prochlorperazine use. South Med J. 1996 Oct;89(10):989-91. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.